EUFLEXXA (1% SODIUM HYALURONATE)
Ferring Pharmaceuticals, Inc. · Decision date Oct 16, 2025
What did the FDA decide?
FDA records P010029/S042 as a supplement to PMA P010029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 16, 2025.
FDA approval order statement
Approval for replacement of the autoclave used for sterilization of the filling machine parts.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Oct 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010029/S042
- Regulatory pathway
- PMA supplement
- Applicant
- Ferring Pharmaceuticals, Inc.
- Product code
- MOZ
- Decision code
- OK30
- Decision date
- Oct 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Ferring Pharmaceuticals, Inc.
- Product code
- MOZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010029. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010029 · Original PMA
EUFLEXXA (1% SODIUM HYALURONATE)
P010029/S042 received
Application receipt date recorded by FDA.
P010029/S042 · FDA decision
30-Day Notice
P010029/S043 · Related supplement
EUFLEXXA (1% sodium hyaluronate)
Timeline entries are records held by MedtechLedger for P010029. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010029
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Ferring Pharmaceuticals, Inc. | PMA approval | Dec 3, 2004 | FDA | |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
SUPARTZ FXP980044/S068 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ferring Pharmaceuticals, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Interpace Pkwy., Parsippany, NJ, 07054
Sources and methodology
- Original FDA record: P010029/S042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


